Prostaglandin Pathway Polymorphisms and HsPDA Treatment Outcomes in Preterm Infants below 32 Weeks: Pilot Study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Genetic variations in the prostaglandin pathway may influence treatment success for preterm infants with a hemodynamically significant patent ductus arteriosus (HsPDA). Further research in diverse populations is recommended for improved therapies.
Area Of Science
- Neonatology
- Genetics
- Pharmacology
Background
- Patent ductus arteriosus (PDA) management in preterm infants remains a challenge, increasing risks of complications.
- Hemodynamically significant PDA (HsPDA) is linked to prematurity factors like low gestational age and ventilation needs.
- Genetic factors are increasingly recognized for influencing drug responses in neonatal conditions.
Purpose Of The Study
- To investigate the impact of prostaglandin pathway gene polymorphisms on pharmacological treatment response in preterm infants with HsPDA.
- To explore genetic influences on the efficacy of PDA treatment.
Main Methods
- Study included neonates born before 32 weeks' gestation.
- Assessed polymorphisms in genes related to the prostaglandin pathway.
- Analyzed treatment success rates in relation to genetic variations.
Main Results
- One specific polymorphism showed a statistically significant association with successful HsPDA treatment.
- Explored differences in therapeutic efficacy based on the specific drug used.
Conclusions
- Genetic variability, particularly in the prostaglandin pathway, may play a role in PDA treatment outcomes.
- Further research with diverse ethnic groups is needed to understand PDA pathophysiology and develop better treatments.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...